Novo Nordisk has closed its internal cell therapy unit and handed Parkinson's disease assets to AI-native Cellular Intelligence.1 The Danish pharma giant is refocusing resources on GLP-1, its proven commercial franchise.1
The move follows a pattern spreading across European pharma. Companies are licensing early-stage programs to AI-specialised partners rather than maintaining broad in-house pipelines. The model reduces capital exposure while retaining future royalty or equity optionality.
NVIDIA has become the central AI infrastructure layer for global drug discovery, anchoring partnerships with Eli Lilly and Thermo Fisher.1 Its BioNeMo platform underpins specialised foundation models at Terray Therapeutics and Apheris.1
Multiple AI biotech platforms launched recently: Boltz, Owkin, Basecamp EDEN, Edison Kosmos, and Natera.1 The stack is maturing from research tools into production-grade drug discovery infrastructure. Investor conviction in Novo Nordisk remains strong amid this transition.1
Pharma's shift to AI platforms is also driven by speed. Traditional early discovery phases take years. AI-native platforms run compound screening at a scale internal teams cannot match. Clinical validation of those gains is ongoing.
For European pharma, the competitive pressure is clear. AI-native startups run more experiments at lower cost than traditional in-house R&D teams.
The externalistation model Novo Nordisk is adopting offers one route forward. Companies retain commercial control of proven assets while outsourcing discovery risk to AI partners. Dependency on platforms still proving clinical translation remains the key exposure.
Regulatory frameworks have not kept pace. Europe's EMA faces pressure to develop clearer standards for AI-generated drug candidates entering clinical pipelines. That gap creates uncertainty for companies moving fast on platform-driven development.
Novo Nordisk's Parkinson's decision is one data point in a larger reorientation. European pharma is concentrating strength on commercial franchises. The R&D frontier is being outsourced to AI-native partners building the new discovery stack.
